NVO vs SNY
Novo Nordisk A/S and Sanofi, both Healthcare
Novo Nordisk A/S is the larger company at $175B against $101B. Over the past year SNY returned -10% against -29% for NVO. The RyuScore puts NVO ahead, 88 against 55 out of 100.
| Figure | NVO | SNY |
|---|---|---|
| Last close | $39.34 | $41.39 |
| Market cap | $175B | $101B |
| 1-year return | -29% | -10% |
| 5-year return | -9.8% | +6.4% |
| RyuScoresector-relative, 1–10 | 88/100 | 55/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Novo Nordisk A/S
Sanofi
Revenue of $24B in H2 2025, net income $2.0B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.